Summary
Lung cancer is currently is the most common cause of death from cancer worldwide. Of total lung cancer incident cases, approximately 85% are the non-small cell lung cancer (NSCLC) subtype. NSCLC patients are usually diagnosed in the later stages of the disease, with poor prognosis. Historically, treatment options for advanced-stage NSCLC patients have been dominated by chemotherapy. However, the launch of targeted therapies such as Iressa (gefitinib) in 2003, Tarceva (erlotinib) in 2004, and Xalkori (crizotinib) in 2011, has shifted the treatment landscape towards personalized medicine.
For the purposes of this report, the author considers the Global NSCLC market to include NSCLC-specific drug sales in the 8MM (US, 5EU [France, Germany Italy, Spain, and the UK], Japan, and China). The current market across these countries is dominated by the sale of major chemotherapy regimens, anti-angiogenic agents and targeted therapies for patients with EGFR+ and ALK+ NSCLC. The author estimated that the Global NSCLC market was valued at $6.2b in 2015. The NSCLC therapeutics market is expected to grow at a positive CAGR of 15.7%, reaching 26.71b in the 8MM by 2025.
The growth of the NSCLC market during the forecast period will be driven partly by increasing incident cases of NSCLC in the US, 5EU, Japan, and China, as the population ages. In addition, the launch of premium-priced immuno-oncology (I/O) and targeted pipeline agents will drive the uptake of new therapies and prolong the duration of treatment in the first-line and beyond. The increased used of branded I/O therapies, such as Keytruda, Opdivo, and Tecentriq will be the primary driver of growth during the forecast period. The projected increase in mutation testing rate during the forecast period coupled with the launch of new generation EGFR and ALK TKIs, and BRAF inhibitors will significantly promote the sales of the targeted therapies, Tagrisso, Alecensa, and Tafinlar + Mekinist.
Highlights
Key Questions Answered
- Based on interviews with key opinion leaders (KOLs), the author has identified the major unmet needs in the NSCLC marketplace. Will the leading pipeline agents fulfil these unmet needs during the forecast period (2015-2025)?
- What research and development (R&D) strategies will companies leverage to compete in the future NSCLC marketplace?
- Which pipeline products are poised to make a major clinical and commercial impact?
- What clinical and commercial factors are likely to influence NSCLC drug uptake in the 8MM?
Key Findings
- The increasing incorporation of premium-priced immune checkpoint inhibitor immunotherapies into the NSCLC treatment algorithm, particularly in the first-line setting, will be one major driver. Collectively, immunotherapies will reach $17.5B in sales by 2025, accounting for roughly 65% of total sales in the NSCLC market. Of the $17.5B total, Keytruda, Opdivo, and Tecentriq are projected to contribute $5.2B, $5.5B, and $2.8B, respectively.
- The increasing incidence of NSCLC in the 8MM will also drive growth. China, in particular, will see its NSCLC incident cases increase dramatically over the forecast period, at an Annual Growth Rate (AGR) of 4.7%. Overall, across the 8MM, the incidence of NSCLC is expected to increase at an AGR of 3.1% from 2015-2025. This increase, coupled with an anticipated increase in branded therapy prescriptions in China, will drive the growth of both the Chinese and global NSCLC markets over the forecast period.
- Patent expiration of several blockbuster drugs, including Tarceva and Alimta, and the uptake of generics will limit growth. The author expects sales of the patented drug in the 8MM to decrease from $783M in 2015 to $18M by 2025. In addition, sales of Alimta will decrease from $2.1B in 2015 to $54M in 2025.
- An increasing emphasis on cost-consciousness is anticipated over the forecast period, which will limit premium pricing opportunities for developers of NSCLC pipeline agents. The author expects this era of austerity and healthcare reform to make it increasingly more difficult for pharmaceutical companies to gain reimbursement approval for their new NSCLC therapies.
Scope
- Overview of NSCLC, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current treatment options.
- Topline NSCLC drug market revenue from 2015-2025, annual cost of therapy (ACOT), and major product sales in 17 patient segments during the forecast period are included.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs, opportunities, R&D strategies, and clinical trial mapping for the NSCLC market.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global NSCLC market. Insightful review of the key industry drivers, restraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global NSCLC therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the NSCLC market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
'
1 Table of Contents
2 Introduction
2.1 Catalyst
2.2 Related Reports
2.3 Upcoming Related Reports
3 Disease Overview
3.1 Etiology and Pathophysiology
3.2 Classification or Staging Systems
3.3 Symptoms
3.4 Prognosis
3.5 Quality of Life
4 Epidemiology
4.1 Disease Background
4.2 Risk Factors and Comorbidities
4.3 Global Trends
4.4 Forecast Methodology
4.5 Epidemiological Forecast for NSCLC (2015-2025) - Base Forecast
4.6 Epidemiological Forecast for NSCLC (2015-2025) - Alternate Forecast
4.7 Discussion
5 Disease Management
5.1 Diagnosis and Treatment Overview
5.2 US
5.3 France
5.4 Germany
5.5 Italy
5.6 Spain
5.7 UK
5.8 Japan
5.9 China
6 Competitive Assessment
6.1 Overview
6.2 Product Profiles - Major Brands, Epidermal Growth Factor Receptor-Targeting
6.3 Product Profiles - Major Brands, Anaplastic Lymphoma Kinase-Targeting
6.4 Product Profiles - Major Brands, Monoclonal Antibodies
6.5 Product Profiles - Major Brands, Other
6.6 Chemotherapies
7 Unmet Needs Assessment and Opportunity Analysis
7.1 Overview
7.2 First-Line Treatments That Extend Overall Survival in Advanced-Stage Nonsquamous NSCLC Without Actionable Mutations
7.3 Therapies Targeting Novel Biomarkers
7.4 Treatment Options for Squamous Patients in the First-Line and Third-Line Setting
7.5 Alternative Testing Options for Patients with Insufficient Biopsy Material
7.6 Treatments for Patients with Acquired Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance
8 Pipeline Assessment
8.1 Overview
8.2 Promising Drugs in Clinical Development
8.3 Promising Drugs in Early-Stage Development
9 Current and Future Players
9.1 Overview
9.2 Trends in Corporate Strategy
9.3 Company Profiles
10 Market Outlook
10.1 Global Markets
10.2 US
10.3 5EU
10.4 Japan
10.5 China
11 Appendix
11.1 Bibliography
11.2 Abbreviations
11.3 Methodology
11.4 Forecasting Methodology
11.5 Primary Research - KOLs
11.6 About
1.1 List of Tables
Table 1: Definitions Used in the AJCC Lung Cancer Staging System
Table 2: AJCC Staging of NSCLC
Table 3: Symptoms of NSCLC
Table 4: Prognostic Factors for NSCLC
Table 5: Prognosis for NSCLC Based on Initial Staging
Table 6: Risk Factors and Comorbidities for Lung Cancer
Table 7: Histological Subtype Distribution Among NSCLC
Table 8: 8MM, Relative Survival
Table 9: 8MM, Sources Used for Diagnosed Incidence of NSCLC
Table 10: 8MM, Sources Used for Cancer Stage at Diagnosis
Table 11: 8MM, Sources Used for NSCLC by Histological Subtypes
Table 12: US, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 13: 5EU, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 14: Japan, Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 15: China (Urban), Sources Used for Diagnosed Incident Cases of NSCLC Segmented by Mutation
Table 16: 8MM, Sources Used for Relative Survival of NSCLC
Table 17: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025
Table 18: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N (Row %), 2015
Table 19: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages =18 Years, N (Row %), 2015
Table 20: 8MM, Diagnosed Incident Cases of NSCLC by Clinical Stage at Diagnosis, Ages =18 Years, N, 2015
Table 21: 8MM, Diagnosed Incident Cases of NSCLC by Histological Subtypes, Ages =18 Years, N, 2015
Table 22: 8MM, Mutations Among Diagnosed Incident Cases of ADC, Both Sexes, Ages =18 Years, N, 2015
Table 23: 8MM, Mutations Among Diagnosed Incident Cases of SCC, Both Sexes, Ages =18 Years, N, 2015
Table 24: 8MM, Mutations Among Diagnosed Incident Cases of NSCLC, Both Sexes, N, Ages =18 Years, 2015
Table 25: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025
Table 26: 8MM, Alternate Forecast, Diagnosed Incident Cases of NSCLC by Histology Subtypes, Ages =18 Years, N, 2015 and 2025
Table 27: 8MM, Alternate Forecast, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025
Table 28: Prevalence of Brain and Bone Metastases in NSCLC
Table 29: Biomarker Testing Rates in Nonsquamous NSCLC
Table 30: Biomarker Testing Rates in Squamous NSCLC
Table 31: Treatment Guidelines for NSCLC
Table 32: Most Prescribed Drugs for NSCLC by Class in the 8MM, 2015-2025
Table 33: Country Profile - US
Table 34: Country Profile - France
Table 35: Country Profile - Germany
Table 36: Country Profile - Italy
Table 37: Country Profile - Spain
Table 38: Country Profile - UK
Table 39: Country Profile - Japan
Table 40: Country Profile - China
Table 41: Leading Treatments for NSCLC, 2016
Table 42: Marketed EGFR TKIs in NSCLC
Table 43: Product Profile - Tarceva
Table 44: Efficacy of Tarceva in First-Line Therapy, EGFR-mutant NSCLC
Table 45: Efficacy of Tarceva in Maintenance Therapy in NSCLC
Table 46: Efficacy of Tarceva in Second- and Third-Line Therapy in NSCLC
Table 47: Safety of Tarceva
Table 48: Tarceva SWOT Analysis, 2016
Table 49: Product Profile - Iressa
Table 50: Efficacy of Iressa in First-Line, EGFR-Mutant NSCLC (Study 1)
Table 51: Efficacy of Iressa in First-Line, EGFR-Mutant ADC NSCLC (Study 2)
Table 52: Safety of Iressa
Table 53: Iressa SWOT Analysis, 2016
Table 54: Product Profile - Gilotrif
Table 55: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 56: Efficacy of Gilotrif in First-Line, EGFR-Mutant ADC
Table 57: Efficacy of Gilotrif in Second-Line, EGFR-Wildtype, EGFR TKI-Naïve, Squamous NSCLC
Table 58: Efficacy of Gilotrif in Fourth-Line, EGFR-Mutant NSCLC
Table 59: Safety of Gilotrif
Table 60: Gilotrif SWOT Analysis, 2016
Table 61: Product Profile - Tagrisso
Table 62: Efficacy of Tagrisso in Second-Line, EGFR-Mutant NSCLC
Table 63: Safety of Tagrisso
Table 64: Tagrisso SWOT Analysis, 2016
Table 65: Product Profile - Portrazza
Table 66: Efficacy of Portrazza in First-Line, Squamous NSCLC
Table 67: Safety of Portrazza
Table 68: Portrazza SWOT Analysis, 2016
Table 69: Efficacy of Conmana in 2L Advanced NSCLC
Table 70: Efficacy of Conmana in 1L EGFR-mutant NSCLC
Table 71: Safety of Conmana
Table 72: Conmana SWOT Analysis, 2016
Table 73: Marketed ALK TKIs in NSCLC
Table 74: Product Profile - Xalkori
Table 75: Efficacy of Xalkori in Treatment-Naïve ALK+ Metastatic NSCLC
Table 76: Efficacy of Xalkori in Previously Treated ALK+ Metastatic NSCLC
Table 77: Safety of Xalkori in Treatment-Naïve, ALK+ Metastatic NSCLC
Table 78: Safety of Xalkori in Previously Treated, Metastatic NSCLC
Table 79: Xalkori SWOT Analysis, 2016
Table 80: Product Profile - Zykadia
Table 81: Efficacy of Zykadia
Table 82: Safety of Zykadia
Table 83: Zykadia SWOT Analysis, 2016
Table 84: Product Profile - Alecensa
Table 85: Efficacy of Alecensa
Table 86: Efficacy of Alecensa in NSCLC patients with CNS lesions
Table 87: Safety of Alecensa
Table 88: Alecensa SWOT Analysis, 2016
Table 89: Marketed PD-1/PD-L1 ICIs in NSCLC
Table 90: Product Profile - Opdivo
Table 91: Efficacy of Opdivo in Metastatic Squamous NSCLC
Table 92: Efficacy of Opdivo in Metastatic Nonsquamous NSCLC
Table 93: Safety of Opdivo
Table 94: Opdivo SWOT Analysis, 2016
Table 95: Product Profile - Keytruda
Table 96: Efficacy of Keytruda
Table 97: Safety of Keytruda
Table 98: Keytruda SWOT Analysis, 2016
Table 99: Product Profile - Tecentriq (atezolizumab)
Table 100: Patient Demographics in the Phase II POPLAR Trial (NCT01903993)
Table 101: Efficacy of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 102: Efficacy of Tecentriq in the Phase III OAK Trial (NCT02008227)
Table 103: Patient Demographics in the Phase II FIR Trial (NCT01846416)
Table 104: Efficacy of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 105: Efficacy of Tecentriq in the Phase II BIRCH Trial (NCT02031458)
Table 106: Safety of Tecentriq in the Phase II POPLAR Trial (NCT01903993)
Table 107: Safety of Tecentriq in the Phase II FIR Trial (NCT01846416)
Table 108: Tecentriq SWOT Analysis, 2016
Table 109: Product Profile - Avastin
Table 110: Efficacy of Avastin in Nonsquamous NSCLC
Table 111: Safety of Avastin
Table 112: Avastin SWOT Analysis, 2016
Table 113: Product Profile - Cyramza
Table 114: Efficacy of Cyramza
Table 115: Safety of Cyramza
Table 116: Cyramza SWOT Analysis, 2016
Table 117: Product Profile - Vargatef
Table 118: Efficacy of Vargatef in ADC NSCLC
Table 119: Safety of Vargatef in ADC NSCLC
Table 120: Vargatef SWOT Analysis, 2016
Table 121: Summary of Chemotherapies, 2015
Table 122: Unmet Need and Opportunity in NSCLC
Table 123: Product Profile - Yervoy (ipilimumab)
Table 124: Demographics in the Phase II NCT00527735 Trial
Table 125: Efficacy of Yervoy + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 126: Demographics in the Phase I CheckMate 012 Trial (NCT01454102)
Table 127: Efficacy of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 128: Safety of Yervoy (ipilimumab) + Carboplatin + Paclitaxel in Advanced NSCLC (NCT00527735)
Table 129: Safety of the Opdivo + Yervoy Combination in the CheckMate 012 Trial (NCT01454102)
Table 130: Yervoy SWOT Analysis, 2016
Table 131: Product Profile - Avelumab (MSB-0010718C)
Table 132: Patient Demographics in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 133: Efficacy of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 134: Efficacy of Avelumab in PD-L1-Positive and -Negative NSCLC
Table 135: Demographics in the Treatment-Naïve NSCLC Cohort in the Phase I Trial (NCT01772004)
Table 136: Efficacy of Avelumab in Treatment-Naïve NSCLC
Table 137: Unconfirmed ORR According to PD-L1 Expression in Treatment-Naïve NSCLC
Table 138: Safety of Avelumab in the Phase Ib Dose-Expansion Study (NCT01772004)
Table 139: Safety of Avelumab in Treatment-Naïve NSCLC (NCT01772004)
Table 140: Avelumab SWOT Analysis, 2016
Table 141: Product Profile - Durvalumab (MEDI4736)
Table 142: Patient Demographics and Disease Characteristics in the Phase I/II NCT01693562 Trial
Table 143: Efficacy of Durvalumab in the Phase I/II NCT01693562 Trial
Table 144: Baseline Characteristics of Patients With Treatment-Naïve NSCLC in the Phase I/II
Table 145: Efficacy of Durvalumab in Treatment-Naïve NSCLC
Table 146: Patient Demographics and Disease Characteristics in the Phase Ib NCT02000947 Trial
Table 147: Efficacy of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 148: Safety of Durvalumab in the Phase I/II Trial (NCT01693562)
Table 149: Safety of Durvalumab in Treatment-Naïve NSCLC
Table 150: Safety of Durvalumab + Tremelimumab in the Phase Ib NCT02000947 Trial
Table 151: Durvalumab SWOT Analysis, 2016
Table 152: Product Profile - Naquotinib Mesylate (ASP8273)
Table 153: Patient Demographics in the Phase I/II NCT02192697 and Phase I NCT02113813 Trials
Table 154: Efficacy of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 155: Safety of Naquotinib in EGFR-Mutant NSCLC in Japanese and US Patients
Table 156: Naquotinib SWOT Analysis, 2016
Table 157: Product Profile - Olmutinib (BI 1482694; HM61713)
Table 158: Demographics in the Phase I/II NCT01588145 Trial
Table 159: Efficacy of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 160: Safety Profile of Olmutinib in the Phase II Portion of the NCT01588145 Trial
Table 161: Olmutinib SWOT Analysis, 2016
Table 162: Product Profile - Dacomitinib
Table 163: Demographics in the Phase II NCT00818441 Trial
Table 164: Efficacy of Dacomitinib in the Phase II NCT00818441 Trial
Table 165: Safety of Dacomitinib in Phase II NCT00818441 Trial
Table 166: Dacomitinib SWOT Analysis, 2016
Table 167: Product Profile - Ensartinib
Table 168: Baseline Patient Characteristics in the Phase I/II eXalt2 Trial (NCT0162534)
Table 169: Efficacy of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 170: Baseline Patient Characteristics in the Expansion Cohort of the Phase I/II eXalt2 Trial
Table 171: Efficacy of Ensartinib in the Expansion Phase of the eXalt2 Trial (NCT0162534)
Table 172: Safety of Ensartinib in the Phase I/II eXalt2 Trial (NCT0162534)
Table 173: Ensartinib SWOT Analysis, 2016
Table 174: Product Profile - Brigatinib
Table 175: Baseline Patient Characteristics in the Phase II ALTA Trial (NCT02094573)
Table 176: Efficacy of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 177: Efficacy of Brigatinib in ALK+ NSCLC with Intracranial CNS Metastases
Table 178: Safety of Brigatinib in the Phase II ALTA Trial (NCT02094573)
Table 179: Brigatinib SWOT Analysis, 2016
Table 180: Product Profile - CimaVax-EGF
Table 181: Demographics in the Phase III trial of the CimaVax-EGF in Cuba
Table 182: Efficacy of the CimaVax-EGF in the Phase III trial in Cuba
Table 183: Safety of the CimaVax-EGF in the Phase III Trial in Cuba
Table 184: CimaVax-EGF SWOT Analysis, 2016
Table 185: Product Profile - Tedopi
Table 186: Demographics in the Phase II Trial of Tedopi in Advanced NSCLC
Table 187: Efficacy of Tedopi in Advanced NSCLC
Table 188: Tedopi SWOT Analysis, 2016
Table 189: Product Profile - Anlotinib
Table 190: Efficacy of Anlotinib in Pretreated NSCLC in the Phase II ALTER0302 Trial
Table 191: Anlotinib SWOT Analysis, 2016
Table 192: Product Profile - Aitan
Table 193: Efficacy of Aitan in Pretreated Nonsquamous NSCLC
Table 194: Aitan SWOT Analysis, 2016
Table 195: Product Profile - Fruquintinib
Table 196: Baseline Demographics in the Phase I Trial (HMP, NCT01645215) of Fruquintinib
Table 197: Efficacy of Fruquintinib in Advanced Solid Tumors
Table 198: Safety of Fruquintinib in Advanced Solid Tumors
Table 199: Fruquintinib SWOT Analysis, 2016
Table 200: Efficacy and Safety of ABP 215 in NSCLC in the Phase III Trial (NCT01966003)
Table 201: Product Profile - Abemaciclib
Table 202: Efficacy of Abemaciclib Monotherapy in Previously Treated NSCLC (NCT01394016)
Table 203: Efficacy of Abemaciclib in Combination with Other Therapies (NCT02079636)
Table 204: Safety of Abemaciclib in Combination with Multiple Single Agents
Table 205: Abemaciclib SWOT Analysis, 2016
Table 206: Product Profile - Tafinlar + Mekinist
Table 207: Demographics in Cohort B of the Pivotal Phase II BRF113928 Trial (GSK, NCT01336634)
Table 208: Efficacy of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
Table 209: Safety of Tafinlar + Mekinist in Previously Treated BRAF V600E+ NSCLC
1.2 List of Figures
Figure 1: 8MM, Diagnosed Incident Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025
Figure 2: 8MM, Age-Specific Diagnosed Incident Cases of NSCLC, Both Sexes, N, 2015
Figure 3: 8MM, Sex-Specific Diagnosed Incident Cases of NSCLC, Ages =18 Years, N, 2015
Figure 4: 8MM, Age-Standardized Diagnosed Incidence of NSCLC, Ages =18 Years, N, 2015
Figure 5: 8MM, Five-Year Diagnosed Prevalent Cases of NSCLC, Both Sexes, Ages =18 Years, N, Select Years 2015-2025
Figure 6: Disease Management Flowchart for nonsquamous NSCLC
Figure 7: Disease Management Flowchart for squamous NSCLC
Figure 8: Disease Management Flowchart for EGFR+ NSCLC
Figure 9: Disease Management Flowchart for ALK+ NSCLC
Figure 10: Tarceva’s Phase III Development in NSCLC
Figure 11: Iressa’s Phase II Development in NSCLC
Figure 12: Gilotrif’s Phase III Development in NSCLC
Figure 13: Tagrisso’s Phase III Development in NSCLC
Figure 14: Portrazza’s Phase II Development in NSCLC
Figure 15: Conmana’s Phase III Development in NSCLC
Figure 16: Xalkori’s Development in NSCLC
Figure 17: Zykadia’s Development in NSCLC
Figure 18: Alecensa’s Development in NSCLC
Figure 19: Opdivo’s Development in NSCLC
Figure 20: Keytruda’s Phase III Development in NSCLC
Figure 21: Tecentriq’s Clincal Development in NSCLC
Figure 22: Avastin’s Phase III Development in NSCLC
Figure 23: Cyramza’s Phase III Development in NSCLC
Figure 24: Vargatef’s Phase II Development in NSCLC
Figure 25: NSCLC - Phase II/III Pipeline, 2016, Part I
Figure 26: NSCLC - Phase II/III Pipeline, 2016, Part II
Figure 27: Competitive Assessment of Late-Stage Pipeline Agents in NSCLC, 2015-2025
Figure 28: Yervoy’s Clinical Development in NSCLC
Figure 29: Clinical and Commercial Positioning of Yervoy
Figure 30: Estimated Sales of Ipilimumab Biosimilars Versus Branded Yervoy in NSCLC, 2015-2025
Figure 31: Avelumab’s Development in NSCLC
Figure 32: Clinical and Commercial Positioning of Avelumab
Figure 33: Durvalumab’s Clinical Development in NSCLC
Figure 34: Clinical and Commercial Positioning of Durvalumab
Figure 35: Naquotinib’s Clincal Development in NSCLC
Figure 36: Clinical and Commercial Positioning of Naquotinib
Figure 37: Olmutinib’s Clincal Development in NSCLC
Figure 38: Clinical and Commercial Positioning of Olmutinib
Figure 39: Dacomitinib’s Clinical Development in NSCLC
Figure 40: Clinical and Commercial Positioning of Dacomitinib
Figure 41: Ensartinib’s Clinical Development in NSCLC
Figure 42: Clinical and Commercial Positioning of Ensartinib
Figure 43: Brigatinib’s Clinical Development in NSCLC
Figure 44: Clinical and Commercial Positioning of Brigatinib
Figure 45: CimaVax-EGF’s Clinical Development in NSCLC
Figure 46: Clinical and Commercial Positioning of CimaVax-EGF
Figure 47: Tedopi’s Clinical Development in NSCLC
Figure 48: Clinical and Commercial Positioning of Tedopi
Figure 49: Anlotinib’s Clinical Development in NSCLC
Figure 50: Clinical and Commercial Positioning of Anlotinib
Figure 51: Aitan’s Clinical Development in NSCLC
Figure 52: Clinical and Commercial Positioning of Aitan
Figure 53: Fruquintinib’s Clinical Development in NSCLC
Figure 54: Clinical and Commercial Positioning of Fruquintinib
Figure 55: Clinical Development of Avastin Biosimilars in NSCLC
Figure 56: Estimated Sales of Bevacizumab Biosimilars Versus Branded Avastin in NSCLC, 2015-2025
Figure 57: Abemaciclib’s Clinical Development in NSCLC
Figure 58: Clinical and Commercial Positioning of Abemaciclib
Figure 59: Tafinlar + Mekinist’s Clinical Development in NSCLC
Figure 60: Clinical and Commercial Positioning of Tafinlar + Mekinist
Figure 61: Veliparib’s Clinical Development in NSCLC
Figure 62: Clinical and Commercial Positioning of Veliparib
Figure 63: MM-121’s Clinical Development in NSCLC
Figure 64: Clinical and Commercial Positioning of MM-121
Figure 65: IMMU-132’s Clinical Development in NSCLC
Figure 66: Clinical and Commercial Positioning of IMMU-132
Figure 67: Plinabulin’s Clinical Development in NSCLC
Figure 68: Clinical and Commercial Positioning of Plinabulin
Figure 69: Global Sales of Branded Products for NSCLC by Company, 2015-2025
Figure 70: Company Portfolio Gap Analysis in NSCLC, 2015-2025
Figure 71: Roche/Genentech SWOT Analysis in NSCLC, 2016
Figure 72: Eli Lilly SWOT Analysis in NSCLC, 2016
Figure 73: Pfizer SWOT Analysis in NSCLC, 2016
Figure 74: AZ SWOT Analysis in NSCLC, 2016
Figure 75: BMS SWOT Analysis in NSCLC, 2016
Figure 76: Merck & Co. SWOT Analysis in NSCLC, 2016
Figure 77: Novartis SWOT Analysis in NSCLC, 2016
Figure 78: BI SWOT Analysis in NSCLC, 2016
Figure 79: Global Sales for NSCLC (8MM), 2015-2025
Figure 80: Global Sales for NSCLC (8MM), 2015-2025
Figure 81: Global Sales for NSCLC (8MM), 2015-2025
Figure 82: Sales for NSCLC in the US by Drug Class, 2015-2025
Figure 83: Sales for NSCLC in the 5EU by Drug Class, 2015-2025
Figure 84: Sales for NSCLC in Japan, 2015-2025
Figure 85: Sales for NSCLC in urban China by Drug Class, 2015-2025
